Key Events This Week
29 Jun: Week opens at Rs.813.00
30 Jun: Stock drops 3.23% to Rs.786.70 amid volume surge
1 Jul: Minor recovery to Rs.790.00 (+0.42%) following rating upgrade announcement
2 Jul: Stock rallies 4.05% to Rs.822.00 on improved valuation and technicals
3 Jul: Week closes lower at Rs.795.00 (-3.28%) despite Sensex gains
29 June 2026: Week Opens Steady at Rs.813.00
Mercury Laboratories began the week at Rs.813.00 on the BSE, with a modest volume of 72 shares traded. The Sensex closed at 35,960.98, setting a neutral tone for the stock’s performance. No major news events were reported on this day, and the stock held steady near recent trading levels.
30 June 2026: Sharp Decline Amid Heavy Volume
The stock experienced a significant decline of 3.23%, closing at Rs.786.70 on increased volume of 504 shares. This drop contrasted with the Sensex’s marginal 0.01% loss, indicating stock-specific pressure. The decline may reflect profit-taking or cautious sentiment ahead of the impending rating update. Despite the fall, the stock remained within its 52-week trading range.
1 July 2026: Rating Upgrade Sparks Mild Recovery
On 1 July, Mercury Laboratories was upgraded by MarketsMOJO from 'Strong Sell' to 'Sell', citing improved valuation and technical indicators. The stock responded positively, gaining 0.42% to close at Rs.790.00, with an intraday high of Rs.833.00. Volume was subdued at 25 shares, suggesting cautious optimism among investors. The Sensex outperformed with a 0.45% gain, reflecting broader market strength.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
2 July 2026: Strong Rally on Valuation Appeal
The stock surged 4.05% to Rs.822.00 on very light volume of 13 shares, outperforming the Sensex’s 0.71% gain. This rally followed the MarketsMOJO upgrade highlighting Mercury Laboratories’ improved valuation metrics, including a price-to-earnings ratio of 18.54 and an enterprise value to EBITDA ratio of 10.73, both attractive relative to pharmaceutical peers. The upgrade also noted a PEG ratio of 0.30, signalling undervaluation relative to earnings growth potential. Despite weak profitability metrics such as an 8.80% ROE and flat operating margins, the stock showed technical resilience.
3 July 2026: Profit Taking Closes Week Lower
Despite the prior day’s gains, Mercury Laboratories retreated 3.28% to close at Rs.795.00 on volume of 23 shares. This decline contrasted with the Sensex’s modest 0.15% advance, underscoring the stock’s volatility and sensitivity to fundamental concerns. The week ended with the stock down 2.21%, underperforming the Sensex’s 1.31% rise. The mixed price action reflects investor caution amid ongoing challenges in financial trends and quality metrics.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-29 | Rs.813.00 | - | 35,960.98 | - |
| 2026-06-30 | Rs.786.70 | -3.23% | 35,958.71 | -0.01% |
| 2026-07-01 | Rs.790.00 | +0.42% | 36,119.01 | +0.45% |
| 2026-07-02 | Rs.822.00 | +4.05% | 36,376.02 | +0.71% |
| 2026-07-03 | Rs.795.00 | -3.28% | 36,431.45 | +0.15% |
Key Takeaways
Valuation Upgrade: The MarketsMOJO upgrade from 'Strong Sell' to 'Sell' on 1 July 2026 was driven by a marked improvement in valuation metrics. Mercury Laboratories now trades at a very attractive price-to-earnings ratio of 18.54 and an EV/EBITDA of 10.73, significantly lower than many pharmaceutical peers. The PEG ratio of 0.30 further supports the stock’s undervaluation relative to growth prospects.
Technical Momentum: The stock showed positive technical signs with a 4.05% rally on 2 July, reaching Rs.822.00, the week’s high. Intraday highs near Rs.833.00 suggest some investor interest despite low volumes.
Fundamental Challenges: Despite valuation appeal, Mercury Laboratories continues to face weak profitability and financial trends. Return on equity stands at 8.80%, and operating profit margins remain subdued at 9.93%. The company’s operating profits have declined at a CAGR of -6.00% over five years, indicating persistent operational challenges.
Price Volatility and Underperformance: The stock’s weekly decline of 2.21% contrasts with the Sensex’s 1.31% gain, reflecting short-term volatility and investor caution. The stock’s underperformance over one year (-7.28%) and mixed returns over longer periods highlight ongoing risks.
Mercury Laboratories Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
Mercury Laboratories Ltd’s week was characterised by a notable upgrade in investment rating reflecting improved valuation and technical momentum, yet tempered by ongoing fundamental weaknesses and price volatility. The stock’s attractive valuation multiples relative to peers offer a compelling entry point, but subdued profitability and flat financial trends warrant caution. The stock’s underperformance against the Sensex this week and over the past year highlights the challenges it faces in regaining investor confidence. Continued monitoring of quarterly results and sector developments will be essential for assessing the stock’s trajectory. For now, the 'Sell' rating signals a cautious stance despite the recent upgrade.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
